The US FDA has approved a label extension for UCB’s Cimzia (certolizumab pegol ... chronic inflammatory disease primarily affecting the skin. Signs and symptoms vary but may include red ...

NICE has recommended in draft guidance that UCB’s Cimzia can receive regular NHS funding ... red scaly plaques on the skin. A digital health passport is an app, or online certification, that ...

In April 2008, certolizumab pegol (Cimzia; UCB), a tumour-necrosis factor blocker, was approved by the US FDA for the treatment of adult patients with moderate-to-severe Crohn's disease who have ...

The updated prescription information on Certolizumab provides an overview of possible side effects, precautions ... failure and menstrual disorder. Skin - Skin inflammation, redness, and hives.